SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001640455-22-000103
Filing Date
2022-11-10
Accepted
2022-11-10 13:46:17
Documents
60
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q jnce-20220930.htm   iXBRL 10-Q 1180365
2 EX-31.1 jnce09302022exhibit311.htm EX-31.1 9186
3 EX-31.2 jnce09302022exhibit312.htm EX-31.2 9194
4 EX-32.1 jnce09302022exhibit321.htm EX-32.1 7517
  Complete submission text file 0001640455-22-000103.txt   5251927

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT jnce-20220930.xsd EX-101.SCH 30321
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT jnce-20220930_cal.xml EX-101.CAL 48497
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT jnce-20220930_def.xml EX-101.DEF 155261
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT jnce-20220930_lab.xml EX-101.LAB 447281
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT jnce-20220930_pre.xml EX-101.PRE 288681
54 EXTRACTED XBRL INSTANCE DOCUMENT jnce-20220930_htm.xml XML 889276
Mailing Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 857-259-3840
Jounce Therapeutics, Inc. (Filer) CIK: 0001640455 (see all company filings)

IRS No.: 454870634 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37998 | Film No.: 221376293
SIC: 2836 Biological Products, (No Diagnostic Substances)